Results 91 to 100 of about 45,933 (222)
PLoS ONE, 2019 BackgroundSignaling through mTOR and somatostatin pathway is implicated in thyroid cancer development.MethodWe evaluated everolimus, an mTOR inhibitor and pasireotide, a multi receptor somatostatin analogue as potential therapy of thyroid cancer focusing
Taofeek K Owonikoko +8 more
doaj +1 more source
Multi‐omics–driven precision medicine
iMeta, EarlyView.Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li +20 more
wiley +1 more source
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
, 2012 Kein-Leong YimVelindre Cancer Center, Cardiff, Wales, United KingdomAbstract: Pancreatic neuroendocrine tumors are rare and the majority of patients present in the advanced stage. Over the past few decades, treatment for patients with metastatic well- or
Yim K-L
core
BMC Cancer, 2011 Background For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has
Huijts Charlotte M +7 more
doaj +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu +2 more
wiley +1 more source
Emerging use of everolimus in the treatment of neuroendocrine tumors
, 2017 Pablo Gajate, Olga Martínez-Sáez, Teresa Alonso-Gordoa, Enrique Grande Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain Abstract: Neuroendocrine tumors (NETs) consist of a diverse family of malignancies, which ...
Grande E +3 more
core
Nail Toxicities Associated With Anticancer Therapies in Children
JEADV Clinical Practice, EarlyView.ABSTRACT Nail toxicities are a frequent yet often underrecognized component of dermatologic adverse events in children receiving anticancer therapies. Both conventional cytotoxic chemotherapy and newer targeted agents can affect the nail matrix, nail bed and periungual tissues, producing a broad spectrum of clinical manifestations that range from ...
Luca Rapparini, Michela Starace
wiley +1 more source
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
, 2013 Rujuta Saksena, Serena T WongThe Cancer Institute of New Jersey, New Brunswick, NJ, USAAbstract: The PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway regulates several key cellular functions and its ...
Wong ST, Saksena R
core
, 2015 Kai Ming Chow,1 Cheuk Chun Szeto,1 Fernand Mac-Moune Lai,2 Cathy Choi-Wan Luk,1 Bonnie Ching-Ha Kwan,1 Chi Bon Leung,1 Philip Kam-Tao Li1 1Department of Medicine and Therapeutics, 2Department of Anatomical and Cellular Pathology, The Chinese University ...
Li PK +6 more
core
透析患者における分子標的薬（Everolimus）による高血糖高浸透圧症候群の1例 [PDF]
, 2019 症例は83歳の男性．24年前糖尿病指摘され5 年前からリナグリプチン，ボグリボース内服し近医で透析中．2 年前左腎癌（pT3N0M0）にて後腹膜鏡下左腎摘術，1 年前多発肺転移が出現し，スニチニブ・アキシチニブ・パゾパニブが無効であり，エベロリムス（Everolimus）に変更した．投与後肺転移巣は縮小傾向であったが，随時血糖が2 週目 350㎎/dL，4 週目 425㎎/dL，8 週目 600㎎/dL となり口渇・全身倦怠感が出現し当科紹介となった．グリコアルブミン 43.7％，血中ケトン体 ...
宮下, 雄博 +9 more
core